PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
215 hedge funds and large institutions have $1.02B invested in PDL BioPharma, Inc. in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 89 increasing their positions, 68 reducing their positions, and 30 closing their positions.
175% more call options, than puts
Call options by funds: $3.98M | Put options by funds: $1.45M
31% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 68
4% less funds holding
Funds holding: 223 → 215 (-8)
17% less capital invested
Capital invested by funds: $1.23B → $1.02B (-$209M)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$39.3M |
| 2 |
GAM
Gotham Asset Management
New York
|
+$23M |
| 3 |
Two Sigma Investments
New York
|
+$13.4M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.68M |
| 5 |
GXMC
Global X Management Company
New York
|
+$7.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$91.1M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$67M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$31.5M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.6M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$12.6M |
PDLI Hedge Fund Activity: Q1 2015 in Review
215 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2015, worth a combined $1.02B — down 17% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PDLI and 23 opened new positions — a net loss of 7 holders — while 68 trimmed existing stakes and 89 added.
The largest buyer was First Trust Advisors, adding an estimated $39.3M. The largest seller was Bank of New York Mellon, cutting an estimated $91.1M.
- 215 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2015, down from 223 in Q4 2014.
- Funds reported $1.02B of PDL BioPharma, Inc. stock for Q1 2015, down 17% quarter-over-quarter.
- 23 funds opened new PDL BioPharma, Inc. positions in Q1 2015 and 30 closed out, a net change of -7 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2015 was First Trust Advisors, an estimated $39.3M added.
- The largest PDL BioPharma, Inc. seller in Q1 2015 was Bank of New York Mellon, an estimated $91.1M sold.
Based on aggregated 13F filings for Q1 2015.